Yiying Wang

Yiying Wang represents companies, investment banks and private equity funds in IPOs in the US and Hong Kong capital markets, cross-border M&A transactions, and various other corporate transactions.

Prior to joining Cooley, Yiying practiced in the Shanghai offices of other leading US law firms and PRC law firm.

Yiying is a native Mandarin speaker and is fluent in English. 

Representative Matters:

Capital Markets

• Leads Biolabs, a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune, and other severe diseases both in China and globally, with a particular focus on diseases that remain untreated by existing therapies, represented by PD-1/PD-L1, on its HK$1.29 billion Hong Kong IPO
• Joint sponsors and underwriters Morgan Stanley, Jefferies, CITIC Securities, CICC and CMB International Securities on HK$1.64 billion IPO and listing of Duality Biotherapeutics, a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases
• Joint sponsors and underwriters CICC and CMB International Securities on HK$$1.005 billion IPO and listing of Zenergy, a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products
• Joint sponsors and underwriters CICC and SPDB International on HK$583 million Hong Kong IPO of BrainAurora Medical Technology, a seasoned player in China's cognitive impairment digital therapeutics (DTx) market
• Joint sponsors and underwriters Morgan Stanley and CICC on HK$335 million IPO and listing of Taimei Technology, a healthtech company that delivers advanced digital solutions for the pharmaceutical and medical device industries
• Jiuyuan Gene Engineering, a modern biopharmaceutical company, specialized in R&D, manufacture and sales of gene engineering, on its HK$563.9 million Hong Kong IPO
• The sole sponsor CICC and other underwriters on HK$791 million (US$101 million) IPO and listing of Laekna, a leading biotechnology company, on HKEX
• ImmuneOnco, a clinical-stage biotech company, on its HK$319 million Hong Kong IPO, and its HK$234 million H share placement
• Akeso Biopharma’s HK$1.2 billion follow-on offerings
• Joint sponsors and underwriters Citi and Huatai International on Cryofocus Medtech's HK$210 million IPO and listing on HKEX
• Asymchem in its US$979 million IPO and listing on the HKEX. This is the largest healthcare HK IPO in 2021.
• Keymed Biosciences in its US$400 million IPO and listing on the HKEX
• Betta Pharmaceuticals Co., Ltd. in its proposed IPO and listing on the HKEX
• Jacobio Pharmaceuticals in its US$174 million IPO and listing on the HKEX
• RemeGen in its US$515 million IPO and listing on the HKEX
• Akeso Biopharma in its US$383 million IPO and listing on the HKEX
• Innovent Biologics in its US$421 million IPO and listing on the HKEX
• Goldman Sachs and Morgan Stanley as underwriters in CStone Pharmaceuticals' US$285 million IPO and listing on the HKEX
• Proposed Hong Kong IPO of Biokin Pharma and Shulan Health
• CooTek in its US$57 million IPO and listing on the NYSE
• VCredit in its US$163 million IPO and listing on the HKEX
• OneSmart in its US$179 million IPO and listing on the NYSE
• Underwriters in Four Season Education's US$101 million IPO and listing on the NYSE
• Secoo in its US$111 million IPO and listing on the NYSE

M&A and Private Equity

• Asymchem in its acquisition of the API Pilot Plant and R&D Laboratory at the former Pfizer UK Sandwich Site, which marks the establishment of Asymchem's first Europe-based R&D and manufacturing hub 
• Lupeng Pharmaceutical in its US$35 million Series Pre-B financing
• Pulnovo Medical in its latest financing round totaling tens of millions of dollars
• Asymchem in its agreement to acquire Snapdragon Chemistry, a US-based chemical technology company
• JD.com and JD Finance in the US$500 million joint ventures for e-commerce and fintech services in Thailand with Central Group, the largest retail conglomerate in Thailand, and Provident Capital
• Ctrip.com in its acquisition of a minority shareholding in mobike Ltd
• Ctrip.com in its acquisition of a minority shareholding in a leading internet company
• Ocean Link, a private equity fund, in its acquisition of a minority shareholding in Ma Feng Wo
• Baidu Inc. in its sales and spin-off of Baidu Waimai
• Unilever in its acquisition of a majority shareholding in a leading Chinese water purifier business
• Alibaba in its acquisition of a minority shareholding in China Business News
• Sequoia Capital (China) in its acquisition of minority shareholdings in various internet companies
• Yunfeng Capital in its acquisition of a minority shareholding in an internet company
• E-House in its acquisition of a minority shareholding in a wealth management company